{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:53:45Z","timestamp":1783511625232,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.canrad.2021.11.015","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:46:25Z","timestamp":1640252785000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Radiotherapy of anal canal cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"D.","family":"Peiffert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moureau-Zabotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rivin Del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-S.","family":"Dietmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2021.11.015_bib0140","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.canrad.2021.11.015_bib0145","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41416-019-0689-x","article-title":"Temporal improvements in locoregional failure and survival in patients with anal cancer treated with chemoradiotherapy: treatment cohort study (1990\u20132014)","volume":"122","author":"Sekhar","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2021.11.015_bib0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2004.09.060","article-title":"Anal canal carcinoma: early-stage tumors<or=10mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy","volume":"62","author":"Ortholan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0155","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0160","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0165","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2021.11.015_bib0170","doi-asserted-by":"crossref","first-page":"665","DOI":"10.21037\/jgo.2016.06.04","article-title":"A comparison between 5-fluorouracil\/mitomycin and capecitabine\/mitomycin in combination with radiation for anal cancer","volume":"7","author":"Peixoto","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0185","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ijrobp.2010.07.1995","article-title":"\u201cMind the gap\u201d--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)","volume":"81","author":"Glynne-Jones","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0190","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2019.08.022","article-title":"Pooled analysis of external-beam radiotherapy parameters in phase II and phase III trials in radiochemotherapy in anal cancer (PARADAC)","volume":"121","author":"Rivin Del Campo","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2021.11.015_bib0200","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0205","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36Gy elective node irradiation dose in anal cancer","volume":"116","author":"L\u00e9pinoy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0215","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1245\/s10434-014-3849-5","article-title":"Chemoradiotherapy with a radiation boost for anal cancer decreases the risk for salvage abdominoperineal resection: analysis from the national cancer data base","volume":"21","author":"Geltzeiler","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0220","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0225","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canrad.2013.02.006","article-title":"[Brachytherapy for anal cancers]","volume":"17","author":"Pommier","year":"2013","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2021.11.015_bib0235","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2021.11.015_bib0240","first-page":"39","article-title":"Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.canrad.2021.11.015_bib0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/COC.0b013e31827e52a3","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity","volume":"37","author":"Mitchell","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0255","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13014-015-0477-6","article-title":"French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients","volume":"10","author":"Vendrely","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.11.015_bib0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5114\/jcb.2019.82804","article-title":"Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis","volume":"11","author":"Arcelli","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.canrad.2021.11.015_bib0265","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ijrobp.2012.09.034","article-title":"Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study)","volume":"85","author":"Moureau-Zabotto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.015_bib0270","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13014-014-0240-4","article-title":"Interstitial high-dose rate brachytherapy as boost for anal canal cancer","volume":"9","author":"Falk","year":"2014","journal-title":"Radiat Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S127832182100305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S127832182100305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:34:59Z","timestamp":1761136499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S127832182100305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S127832182100305X"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2021.11.015","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy of anal canal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2021.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}